Product Details: PE 22-28 Peptide

PE 22-28 (or PE22.28) is an endogenous peptide. It is derived from the naturally occurring peptide spadin. It is the same compound investigated for its interaction with potassium channel systems in experimental models. It is classified as a TREK-1 channel modulator. It is studied in laboratory environments for its role in neuronal signaling and ion channel regulation.

In research settings, pe22-28 peptide is examined for its interaction with neurobiological pathways. These are particularly those associated with potassium channel activity and neuronal excitability. Its structural composition of seven amino acids has enhanced stability compared to its parent compound. Due to this, it is utilized in biochemical and neuroscience research applications.

Researchers investigate PE 22-28 in controlled models to explore:

• TREK-1 potassium channel inhibition mechanisms
• neuronal excitability and ion channel regulation
• peptide stability and structure-function relationships
• neurotransmitter signaling pathways in experimental systems

Mechanism of Action

PE 22-28 is investigated for its ability to inhibit the TREK-1 potassium channel. It is a channel involved in regulating neuronal excitability in experimental models. Studies suggest that the compound displays high binding affinity. This allows researchers to examine its influence on ion channel activity and associated signaling pathways.

Through TREK-1 channel inhibition, PE 22-28 is studied for its role in modulating neuronal signaling dynamics. This interaction allows researchers to analyze downstream effects on neurotransmitter systems, synaptic activity, and cellular signaling processes in controlled laboratory environments.

Properties of PE 22-28:

• Molecular Formula: C35H55N11O9
• Molecular Weight: 773.89 g/mol
• CAS Number: 1801959-12-5
• IUPAC Name: glycyl-L-valyl-L-seryl-L-tryptophylglycyl-L-leucyl-L-arginine, acetate
• Synonyms: Gly-Val-Ser-Trp-Gly-Leu-Arg-OH

PE 22-28 Peptide Benefits:

TREK-1 Channel Inhibition Studies:

The primary pe 22 28 peptide benefit is its interaction with TREK-1 potassium channels. All of it is done in preclinical models. Experimental findings suggest that channel inhibition may affect neuronal signaling pathways and ion channel regulation mechanisms.

Neuronal Signaling Research:

PE 22-28 is studied in laboratory systems. It is to evaluate its effects on neuronal excitability and neurotransmitter signaling processes. These investigations focus on how ion channel modulation influences cellular communication in experimental environments.

Neurogenesis and Synaptic Activity Analysis:

This peptide is utilized in research models. It is used to examine processes related to synaptic signaling and neuronal network dynamics. Studies are trying to find how peptide interactions contribute to changes in cellular signaling pathways.

Peptide Stability and Structure-Function Studies:

PE 22-28 is also investigated in biochemical assays. It is to evaluate peptide stability, binding affinity, and structure-function relationships compared to its parent compound.

Why Choose BehemothLabz to Buy PE 22-28 Peptide

Choose Behemoth Labz for high-quality research compounds developed to meet strict laboratory standards. Our PE 22-28 Peptide is produced under controlled conditions and undergoes third-party testing to verify purity, composition, and consistency.We ensure secure handling, reliable sourcing, and safe delivery channels for all research materials. Our commitment to quality and transparency supports advanced experimental research and peptide-based investigations.

Disclaimer:

This information is for educational purposes. We do not allow the human consumption of our products. All our products are sold for laboratory and research experiments.

ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

References:

• Kumar M, Balyan K, Debnath E, Himtsoe B, Sapna S, Kumar A.
• Pregnancy Hypertens. 2023 Dec;34:39-46. doi: 10.1016/j.preghy.2023.09.005. Epub 2023 Oct 4.
• PMID: 37801800 https://pubmed.ncbi.nlm.nih.gov/37801800/
• Borsotto, M., Veyssiere, J., Moha ou Maati, H., Devader, C., Mazella, J., & Heurteaux, C. (2015). Targeting TREK-1 channel for neuroprotection: Spadin and its analogs. Frontiers in Pharmacology, 6, 248. https://pubmed.ncbi.nlm.nih.gov/26528136/